A Japanese multicenter comparison of iotrolan 280 with iopamidol 300 in intravenous urography

A multicenter study was carried out to compare iotrolan 280, a non-ionic, dimeric water-soluble contrast agent, with iopamidol 300 a non-ionic, monomeric agent, to assess visualization, safety and clinical benefit in intravenous urography. Both iotrolan and iopamidol showed a high rate of effective visualization. Iotrolan was significantly better than iopamidol in visualizing the renal pelvis. Adverse reactions did not differ significantly between the two contrast agents, and no severe reactions developed. Both contrast agents were clinically valuable in over 95% of patients. There was no significant difference between the two patient groups in clinical benefit. Iotrolan has been demonstrated to be clinically comparable to iopamidol and is thus very suitable for use in intravenous urography.